Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome

Trial Profile

A phase Ia trial of SEL-212 for treatment of refractory and tophaceous gout and tumor lysis syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SEL 212 (Primary)
  • Indications Gout; Tumour lysis syndrome
  • Focus Adverse reactions; Proof of concept
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 07 Dec 2016 Results published in the Selecta Biosciences Media Release
    • 07 Dec 2016 According to a Selecta Biosciences media release, all patient visits has been completed in this and other Phase I trial (266205).
    • 26 Oct 2016 Results from this and another phase I trial will be presented at the 11th Annual Immunization and Vaccine Summit (IMVACS) 2016, according to a Selecta Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top